研究者業績
基本情報
- 所属
- 藤田医科大学 精神・神経病態解明センター 神経行動薬理学研究部門 助教
- 学位
- 修士(保健学)(藤田医科大学)博士(医療科学)(藤田医科大学)
- J-GLOBAL ID
- 202301015528900092
- researchmap会員ID
- R000051067
- 外部リンク
研究分野
1経歴
1-
2022年4月 - 現在
学歴
3-
2020年4月 - 2023年3月
-
2018年4月 - 2020年3月
-
2014年4月 - 2018年3月
受賞
3-
2025年3月
-
2019年3月
論文
17-
International Journal of Molecular Sciences 26(11) 5184-5184 2025年5月28日 査読有り筆頭著者Schizophrenia is a psychiatric disorder characterized by positive, negative, and cognitive symptoms. MK-801, an N-methyl-D-aspartate receptor antagonist, has been used to induce schizophrenia-like behaviors in animal models. Here, we employed IntelliCage, an automated system used for tracking behavior, to assess schizophrenia-like behaviors in MK-801-treated mice under semi-naturalistic conditions. Mice that had been treated with MK-801 for 2 weeks were analyzed for locomotion, emotional, and cognitive functions. Repeated MK-801-treated mice exhibited transient hyperactivity in a novel environment, without significant changes in overall circadian activity. Sucrose preference remained intact, suggesting preserved reward sensitivity. However, less time spent in the corner during the early phase of the competition test indicated reduced competitive behavior for limited water rewards. In the behavioral flexibility test, repeated MK-801-treated mice showed impaired reversal learning, suggesting reduced cognitive flexibility, although the acquisition of initial place discrimination was comparable to that observed in control mice. These behavioral impairments parallel core symptoms of schizophrenia, particularly in the social and cognitive domains. Our findings demonstrate the utility of IntelliCage in detecting behavioral phenotypes over prolonged periods in group-housed settings. This study provides an ecologically valid platform for assessing schizophrenia-like behaviors and may facilitate the development of translationally relevant therapeutic interventions.
-
Molecular Neurobiology 2025年5月14日 査読有り
-
British Journal of Pharmacology 2024年12月10日 査読有りBackground and Purpose Alterations in tryptophan‐kynurenine (TRP‐KYN) pathway are implicated in major depressive disorder (MDD). α7 nicotinic acetylcholine (α7nACh) receptor regulates the hypothalamic–pituitary–adrenal (HPA) axis. We have shown that deficiency of kynurenine 3‐monooxygenase (KMO) induces depression‐like behaviour via kynurenic acid (KYNA; α7nACh antagonist). In this study, we investigated the involvement of the TRP‐KYN pathway in stress‐induced behavioural changes and the regulation of the HPA axis. Experimental Approach Mice were exposed to chronic unpredictable mild stress (CUMS) and subjected to behavioural tests. We measured TRP‐KYN metabolites and the expression of their enzymes in the hippocampus. KMO heterozygous mice were used to investigate stress vulnerability. We also evaluated the effect of nicotine (s.c.) on CUMS‐induced behavioural changes and an increase in serum corticosterone (CORT) concentration. Key Results CUMS decreased social interaction time but increased immobility time under tail suspension associated with increased serum corticosterone concentration. CUMS increased KYNA levels via KMO suppression with microglial decline in the hippocampus. Kmo+/− mice were vulnerable to stress: they exhibited social impairment and increased serum corticosterone concentration even after short‐term CUMS. Nicotine attenuated CUMS‐induced behavioural changes and increased serum corticosterone concentration by inhibiting the increase in corticotropin‐releasing hormone. Methyllycaconitine (α7nACh antagonist) inhibited the attenuating effect of nicotine. Conclusions and Implications CUMS‐induced behavioural changes and the HPA axis dysregulation could be induced by the increased levels of KYNA via KMO suppression. KYNA plays an important role in the pathophysiology of MDD as an α7nACh antagonist. Therefore, α7nACh receptor is an attractive therapeutic target for MDD.
-
Biochemical and Biophysical Research Communications 737 150922-150922 2024年12月 査読有り
-
Molecular Psychiatry 2024年11月29日 査読有り
MISC
13-
日本神経化学会大会抄録集(Web) 65th 2022年
所属学協会
3共同研究・競争的資金等の研究課題
4-
武田科学振興財団 医学系研究助成 2025年7月 - 2028年5月
-
日本学術振興会 科学研究費助成事業 2024年4月 - 2027年3月
-
日本学術振興会 科学研究費助成事業 2024年4月 - 2026年3月
-
公益財団法人 堀科学芸術振興財団 第1部 医学系若手研究者プロジェクト 2024年4月 - 2025年3月
産業財産権
1メディア報道
4-
EurekAlert! 2025年7月 インターネットメディア
-
EurekAlert! 2024年9月24日 インターネットメディア